Claims for Patent: 8,217,020

Summary for Patent: 8,217,020

Title:	Methods and compositions for reducing viral genome amounts in a target cell
Abstract:	Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target cell. Also provided are pharmaceutical compositions, kits and systems for use in practicing the subject methods. The subject invention finds use in a variety of applications, including the treatment of subjects suffering from a viral mediated disease condition, e.g., an HCV mediated disease condition.
Inventor(s):	Sarnow; Peter (Palo Alto, CA), Jopling; Catherine L. (Liverpool, GB), Lancaster; Alissa M. (Portland, OR)
Assignee:	The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Application Number:	12/950,672
Patent Claims:	1. A method of treating a subject infected with Hepatitis C (HCV) virus comprising: administering to said subject an miRNA inhibitory agent targeted to miR-122, wherein said miRNA inhibitory agent comprises an antisense oligonucleotide complementary to said miR-122. 2. The method of claim 1, wherein said subject is a human. 3. The method of claim 1, wherein said subject is a mammal. 4. The method of claim 1, wherein said antisense oligonucleotide is completely complementary to said miR-122. 5. The method of claim 1, wherein said antisense oligonucleotide comprises the nucleotide sequence of SEQ ID NO:18. 6. The method of claim 1, wherein said antisense oligonucleotide comprises the nucleotide sequence of SEQ ID NO:15. 7. The method of claim 1, wherein said subject is infected with HCV-1a. 8. The method of claim 1, wherein said subject is infected with HCV-1b. 9. The method of claim 1, wherein said subject is infected with HCV-2. 10. The method of claim 1, wherein said subject is infected with HCV-3. 11. The method of claim 1, wherein said subject is infected with HCV-4. 12. The method of claim 1, wherein said subject is infected with HCV-5. 13. The method of claim 1, wherein said subject is infected with HCV-6. 14. The method of claim 1, further comprising administering at least one additional agent selected from the group consisting of an antiviral agent and an interferon. 15. The method of claim 14, wherein said at least one additional agent comprises an antiviral agent. 16. The method of claim 14, wherein said at least one additional agent comprises an interferon. 17. The method of claim 16, wherein said interferon comprises interferon alfa-2b. 18. The method of claim 16, wherein said interferon comprises interferon alfa-2a. 19. The method of claim 16, wherein said interferon comprises interferon alfacon-1. 20. The method of claim 16, wherein the interferon comprises a pegylated interferon. 21. The method of claim 14, wherein said antiviral agent comprises ribavirin. 22. The method of claim 1, wherein said antisense oligonucleotide comprises a 2'-O-methyl modification.

Details for Patent 8,217,020

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2024-05-04
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2024-05-04
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2024-05-04
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663	10/06/1997		2024-05-04
Hoffmann-la Roche Inc.	PEGASYS COPEGUS COMBINATION PACK	peginterferon alfa-2a and ribavirin		125083	06/04/2004		2024-05-04
Schering Corporation A Subsidiary Of Merck & Co., Inc.	PEGINTRON/ REBETOL COMBO PACK	peginterferon alfa-2b and ribavirin		125196	06/13/2008		2024-05-04